Temporal control of voicing in Parkinson's disease and tardive dyskinesia speech

被引:0
|
作者
Fraïle, V [1 ]
Cohen, H [1 ]
机构
[1] Univ Quebec, Cognit Neurosci Lab, Montreal, PQ H3C 3P8, Canada
关键词
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Basal ganglia disorders are associated with a set of clinical syndromes characterized by various motor disabilities. The hypocinetic syndromes, of which Parkinson's disease (PD) is the prototype, are mainly marked by a paucity and a slowing down of motor function, while the hypercinetic disorders, and among them tardive dyskinesia (TD), are mainly distinguished by involuntary and abnormal movements. The abnormal speech motor control is part of the parkinsonian semiology, but little is known about the specific speech alterations in TD. In the present acoustic study, the motor control capabilities of PD and TD subjects were compared in a sentence production task. Three temporal measures were used: sentence duration, total number of pauses, and ratio of total pause duration to total sentence duration. Analyses of data revealed a significant decrease of voiceless speech periods in the two clinical groups, relative to controls, but most markedly in TD subjects. These data indicate that TD is not only characterized by involuntary movements but also by a disturbance of voluntary motor control. The results also revealed that, in spite of their clinical and neurophysiological differences, PD and TD also share similar patterns of deficits. (C) 1999 Academic Press.
引用
收藏
页码:118 / 122
页数:5
相关论文
共 50 条
  • [1] Aripiprazole induced tardive dyskinesia in a patient with Parkinson's disease
    Agarwal, P.
    Griffith, A.
    Hall, D. A.
    [J]. MOVEMENT DISORDERS, 2008, 23 (01) : S236 - S237
  • [2] Improvement of voicing in patients with Parkinson's disease by speech therapy
    de Swart, BJM
    Willemse, SC
    Maassen, BAM
    Horstink, MWIM
    [J]. NEUROLOGY, 2003, 60 (03) : 498 - 500
  • [3] Fluoxetine-induced tardive dyskinesia in a patient with Parkinson's disease
    Raidoo, Deshandra M.
    [J]. ACTA NEUROPSYCHIATRICA, 2012, 24 (05) : 306 - 309
  • [4] Improvement of voicing in patients with Parkinson's disease by speech therapy - Reply
    de Swart, BJM
    Willemse, SC
    Horstink, MWIM
    Maassen, BAM
    [J]. NEUROLOGY, 2003, 61 (09) : 1316 - 1317
  • [5] Antidyskinetic efficacy of sarizotan in animal models of Parkinson's disease and tardive dyskinesia
    Bartoszyk, GD
    Rosengarten, H
    Schmidt, WJ
    [J]. ANNALS OF NEUROLOGY, 2005, 58 : S19 - S19
  • [6] Speech Rate Mediated Vowel and Stop Voicing Distinctiveness in Parkinson's Disease
    Knowles, Thea
    Adams, Scott G.
    Jog, Mandar
    [J]. JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH, 2021, 64 (11): : 4096 - 4123
  • [7] Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2
    Pham, DQ
    Plakogiannis, R
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (12) : 2065 - 2072
  • [8] SPEECH ABNORMALITIES IN TARDIVE-DYSKINESIA
    GERRATT, BR
    GOETZ, CG
    FISHER, HB
    [J]. ARCHIVES OF NEUROLOGY, 1984, 41 (03) : 273 - 276
  • [9] SPEECH ABNORMALITIES IN TARDIVE-DYSKINESIA
    KHAN, R
    JAMPALA, VC
    DONG, K
    VEDAK, CS
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1994, 151 (05): : 760 - 762
  • [10] A brain-derived neurotrophic factor polymorphism in Caucasians with tardive dyskinesia and Parkinson's disease
    Tsapakis, E. M.
    Scully, P.
    Quinn, J.
    Wright, P.
    Smith, S.
    Daly, A.
    Waddington, J.
    Aitchison, K.
    [J]. SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 507 - 507